ENDPOINTS NEWS3h
Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more
AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...
ENDPOINTS NEWS16h
Il­lu­mi­na seeks to dis­miss share­hold­er law­suit, de­nies se­cret $800M stake
Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...
ENDPOINTS NEWS22h
Eye­n­ovia halts Phase 3 my­opia tri­al, to con­sid­er sell­ing as­sets
Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...
ENDPOINTS NEWS19h
Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy
Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...
ENDPOINTS NEWS22h
Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors
Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...
ENDPOINTS NEWS23h
Vi­tal­li ends work on Dae­woong as­set; Alec­tor’s $50M loan
Vitalli Bio ends Daewoong deal, Alector receives $50M Hercules Capital loan, Bavarian Nordic gets $340M vaccine orders, Nuvectis Pharma reports disappointing trial data, Flashpoint partners with Saudi ...